Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896874 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL3378405 | 0.77 | — | — | |
| SCHEMBL4574829 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL20267072 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL24438361 | 0.75 | ALDH1A1 (0.48) | MEN1KMT2AMMP1MMP3HTT | |
| SCHEMBL8432009 | 0.75 | ALDH1A1 (0.48) | MEN1KMT2AMMP1MMP3HTT | |
| SCHEMBL9056224 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL2703509 | 0.73 | HTT (0.52) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL2704732 | 0.73 | L3MBTL1 (0.55) | SMN1; SMN2CA12CA1CA9MEN1 | |
| SCHEMBL9532761 | 0.71 | GPX4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440517-B1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-03-26 | — | — | EP | claimed |
| EP-0888351-B1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | THOMAE GMBH DR K (DE) | 2003-10-15 | — | — | EP | claimed |
| EP-0589446-B1 | N-(Hydroxyethyl)butanediamide derivatives as renin inhibitors | BOEHRINGER INGELHEIM CA LTD (CA) | 1997-09-03 | — | — | EP | claimed |
| EP-0480455-B1 | Optically active thienotriazolodiazepine compounds | YOSHITOMI PHARMACEUTICAL (JP) | 1997-01-22 | — | — | EP | claimed |
| EP-0589445-B1 | Renin Inhibiting N-(2-Amino-2-oxoethyl)Butanediamide Derivatives | BIO MEGA BOEHRINGER INGELHEIM (CA) | 1997-01-15 | — | — | EP | claimed |
| US-12421207-B2 | Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2025-09-23 | — | — | US | disclosed |
| US-20250171426-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2025-05-29 | — | — | US | disclosed |
| EP-4479397-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG Pharmaceutical Co., Ltd. (KR) | 2024-12-25 | — | — | EP | disclosed |
| CN-119032087-A | Pyrimidinedione-based compounds as AXL, C-MET and MER inhibitors and methods of use thereof | CMG制药株式会社 | 2024-11-26 | — | — | CN | disclosed |
| EP-4420732-A2 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3233863-B1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20220281871-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-09-08 | — | — | US | disclosed |
| CN-107207514-B | Fused heteroaryl compounds and their use as TRK inhibitors | 康联制药有限公司 | 2020-01-24 | — | — | CN | disclosed |
| EP-3233863-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2017-10-25 | — | — | EP | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| WO-2016097869-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| WO-1996040753-A1 | PIPECOLIC ACID DERIVATIVES OF PROLINE THREONINE AMIDES USEFUL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, MET, AXL | SMN1; SMN2 3989/4885CA12 3445/4885CA1 4041/4885 |
| US-20250171426-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, AXL, RET | SMN1; SMN2 3670/4885CA12 4278/4885CA1 4387/4885 |
| US-20220281871-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK13, CDK1 | SMN1; SMN2 1816/4885CA12 4459/4885CA1 4158/4885 |
| US-12421207-B2 | Pyrimidinedione-based compounds as AXL, c-MET, and Mer inhibitors and methods of use thereof | MERTK, AXL, MET | SMN1; SMN2 3855/4885CA12 4279/4885CA1 4361/4885 |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | NR4A3, NR4A1, NR3C1 | SMN1; SMN2 1020/4885CA12 4749/4885CA1 4578/4885 |
| US-20230348423-A1 | PYRIMIDINEDIONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, AXL, MET | SMN1; SMN2 3855/4885CA12 4279/4885CA1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.